ABBV · News · 20260806N

Guidance / Outlook

AbbVie Inc. · 2026-08-06 · Importance 51 · Surprise 60

AbbVie reduced its 2026 EPS outlook to reflect the pending Apogee acquisition. The transaction is expected to dilute adjusted EPS by $0.14, partially offsetting the benefit of the 2026 revenue guidance increase. The guidance change followed a second-quarter revenue result of $16.99 billion and adjusted EPS of $3.65.

Key facts